Qiaonan Duan
Affiliations: | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Google:
"Qiaonan Duan"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hodos R, Zhang P, Lee HC, et al. (2018) Cell-specific prediction and application of drug-induced gene expression profiles. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 23: 32-43 |
| Niepel M, Hafner M, Duan Q, et al. (2017) Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nature Communications. 8: 1186 |
| Sangodkar J, Perl A, Tohme R, et al. (2017) Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The Journal of Clinical Investigation |
| Niepel M, Hafner M, Duan Q, et al. (2017) Abstract IA05: New methods and better theory for pre-clinical cancer pharmacogenomics Cancer Research. 77 |
| Duan Q, Reid SP, Clark NR, et al. (2016) L1000CDS(2): LINCS L1000 characteristic direction signatures search engine. Npj Systems Biology and Applications. 2 |
| Wang Z, Monteiro CD, Jagodnik KM, et al. (2016) Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd. Nature Communications. 7: 12846 |
| Kuleshov MV, Jones MR, Rouillard AD, et al. (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Research |
| Dohlman A, Zaman S, Duan Q, et al. (2016) Predicting adverse cardiovascular events for tyrosine kinase inhibitors from molecular features F1000research. 5 |
| Hafner M, Niepel M, Duan Q, et al. (2016) Abstract 788: Transcriptional landscape of drug response guides the design of potent and synergistic drug combinations Cancer Research. 76: 788-788 |
| Hafner M, Niepel M, Duan Q, et al. (2015) Abstract PR16: Transcriptional landscape of drug response guides the design of specific and potent drug combinations Cancer Research. 75 |